What to expect when a sore joint gets checked

What to tell the provider first

Start with the daily task you can't do comfortably now. Say when the ache began and point to where it hurts. Mention swelling, weakness, or a catching feeling. Bring your current medicines and reports from earlier visits.

Plain words work well during this talk. Explain which activities help and which ones hurt most. Include any fall, injury, or surgery. They'll use your answers to decide what to check first.

What to expect during the exam

The medical provider is the health care person who examines you. First, that provider asks about your health and daily limits. Then the joint is checked for movement, strength, swelling, and sore areas. You won't always need a new X-ray if an old one has useful detail.

QC Kinetix may discuss biologic therapies after the exam. This means the team draws your blood and prepares part of it there. They place the prepared part at the sore area without joint surgery. They'll also explain when care from another doctor makes more sense.

What to ask before choosing care

Ask what probably made the joint sore. Then ask why the offered treatment matches that cause. Ask exactly what would be placed at the sore area. Request the whole price on paper before deciding.

Find out what recovery could feel like. Ask how soon you could walk, drive, or use the arm again. Ask when any relief could begin. Finally, ask what happens if your soreness doesn't improve.

Sources

1. A Bayesian network meta-analysis of 48 Level I-II randomized trials (9,338 knees) with a minimum 6-month follow-up ranked the four commonest intra-articular injections. HA and PRP both significantly improved pain versus placebo; HA, PRP and BMAC all significantly improved function versus placebo. SUCRA rankings were PRP 91.54, BMAC 76.46, HA 53.12, corticosteroid 15.18 and placebo 13.70 - corticosteroid ranked barely above placebo at six months and beyond.

   Jawanda H, et al. — Platelet-Rich Plasma, Bone Marrow Aspirate Concentrate, and Hyaluronic Acid Injections Outperform Corticosteroids in Pain and Function Scores at a Minimum of 6 Months as Intra-Articular Injections for Knee Osteoarthritis: A Systematic Review and Network Meta-analysis.. Arthroscopy, 2024. DOI: 10.1016/j.arthro.2024.01.037.

2. A network meta-analysis of 43 trials (5,554 patients) reached the OPPOSITE ranking to the more recent orthobiologic-favourable reviews: steroids ranked most likely to be effective for pain and function, with adipose MSC and multiple PRP ranked LEAST likely; single PRP, multiple PRP and adipose MSC did not produce a relevant reduction in pain or improvement in function versus placebo. The authors noted treatment-effect differences were small and potentially not clinically meaningful either way.

   Han SB, et al. — Intra-Articular Injections of Hyaluronic Acid or Steroids Associated With Better Outcomes Than Platelet-Rich Plasma, Adipose Mesenchymal Stromal Cells, or Placebo in Knee Osteoarthritis: A Network Meta-analysis.. Arthroscopy, 2021. DOI: 10.1016/j.arthro.2020.03.041.

3. A network meta-analysis restricted to LARGE randomized trials (at least 100 patients per group; 57 RCTs, 22,795 participants, 18 intra-articular interventions) found treatment effects were consistently larger in the 35 high-risk-of-bias trials than in the 22 low/unclear-risk trials. In the main analysis excluding high-risk trials, triamcinolone had the highest probability of exceeding the minimal important difference at weeks 2 and 6; hyaluronic acid had no effect on pain (SMD -0.04, 95% CrI -0.19 to 0.11, 11 trials) but higher odds of dropouts due to adverse events (OR 2.01) and of serious adverse events (OR 1.86). The effects of 16 of the 18 interventions were smaller than the MID and most were consistent with placebo effects.

   Pereira TV, et al. — Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis.. Osteoarthritis and Cartilage, 2025. DOI: 10.1016/j.joca.2024.08.014.

4. A meta-analysis of 34 RCTs (1,403 PRP knees vs 1,426 controls) found WOMAC favoured PRP over placebo at 12 months and over hyaluronic acid at 6 and 12 months, and favoured PRP over steroids on VAS pain, KOOS pain, daily function and quality of life at 6 months. Crucially, the authors state that the superiority of PRP DID NOT REACH the minimal clinically important difference for any outcome and the quality of evidence was low.

   Filardo G, et al. — PRP Injections for the Treatment of Knee Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials.. Cartilage, 2021. DOI: 10.1177/1947603520931170.

5. A network meta-analysis of 64 trials (9,710 patients) that deliberately separated WITHIN-CLASS variants found high-molecular-weight hyaluronic acid was the only treatment whose confidence interval lay entirely above the minimal important difference for BOTH pain and function. PRP's pain estimate also cleared the MID but varied across sensitivity analyses, leaving its efficacy uncertain; extended-release corticosteroid showed possible benefit over standard-release corticosteroid.

   Phillips M, et al. — Differentiating factors of intra-articular injectables have a meaningful impact on knee osteoarthritis outcomes: a network meta-analysis.. Knee Surgery, Sports Traumatology, Arthroscopy, 2020. DOI: 10.1007/s00167-019-05763-1.

6. A systematic mapping of the entire injectable knee OA literature since 1959 identified 766 clinical studies covering 75,834 patients: 11,245 treated with corticosteroid, 40,862 with hyaluronic acid, 16,174 with PRP and 7,553 with cell-based therapies. Hyaluronic acid still has the largest evidence base; PRP has recently overtaken corticosteroid in number of studies; placebo-controlled RCTs remain limited and only a negligible percentage of studies examined disease-modifying effects.

   Bensa A, et al. — Corticosteroids, hyaluronic acid, platelet-rich plasma, and cell-based therapies for knee osteoarthritis - literature trends are shifting in the injectable treatments' evidence: a systematic review and expert opinion.. Expert Opinion on Biological Therapy, 2025. DOI: 10.1080/14712598.2025.2465833.